placeholder image
N. P. Klein All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Association of respiratory syncytial virus vaccination during pregnancy with adverse obstetric and neonatal outcomes. 
    Obstetrics and Gynecology. 2026
  • Effectiveness of 2023-2024 coronavirus disease 2019 (COVID-19) vaccines in pregnant women. 
    Obstetrics and Gynecology. 2026
  • Estimated effectiveness of 2024-2025 COVID-19 vaccines in adults. 
    JAMA internal medicine. 2026
  • Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024. 
    Vaccine. 2026
  • Influenza activity and estimated vaccine effectiveness during the 2025-2026 influenza season. 
    JAMA network open. 2026
  • Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults - United States, 2024-25 season. 
    medRxiv. 2026
  • Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults-VISION, United States, 2024-2025 season. 
    Open forum infectious diseases. 2026
  • Interim estimated effectiveness of 2025-2026 COVID-19 vaccines in adults using a test-negative design. 
    JAMA network open. 2026
  • Interim estimates of 2025-26 seasonal influenza vaccine effectiveness - United States, September 2025-February 2026. 
    MMWR: Morbidity and Mortality Weekly Report. 2026
  • Role of vaccine age restrictions on rotavirus vaccine coverage, Vaccine Safety Datalink 2018-2024. 
    Journal of the Pediatric Infectious Diseases Society. 2026
  • 18 years - VISION and IVY Networks, September 2024-January 2025. 
    MMWR: Morbidity and Mortality Weekly Report. 2025
  • COVID-19 and completion of select routine childhood vaccinations. 
    Pediatrics. 2025
  • Coronavirus disease 2019 (COVID-19) vaccination and spontaneous abortion. 
    Obstetrics and Gynecology. 2025
  • Effectiveness of 2023-2024 COVID-19 vaccines in children in the United States. 
    Pediatrics. 2025
  • Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age. 
    Vaccine. 2025
  • Effectiveness of 2024-2025 COVID-19 vaccines in children in the United States - VISION, August 29, 2024-September 2, 2025. 
    MMWR: Morbidity and Mortality Weekly Report. 2025
  • Estimated 2023-2024 COVID-19 vaccine effectiveness in adults. 
    JAMA network open. 2025
  • Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. 
    Clinical Infectious Diseases. 2025
  • Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025. 
    MMWR: Morbidity and Mortality Weekly Report. 2025
  • JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States. 
    Infection. 2025
  • Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the Vaccine Safety Datalink. 
    Vaccine. 2025
  • Patterns in prescribing and dispensing of influenza antivirals among adults with influenza presenting to urgent care and emergency department settings, VISION Network, 2023-2024. 
    Clinical Infectious Diseases. 2025
  • Risk of immune thrombocytopenic purpura recurrence following second measles-containing vaccine dose. 
    Pediatrics. 2025
  • Vaccination during pregnancy in the Vaccine Safety Datalink, 2002-2022. 
    Pediatric Infectious Disease Journal. 2025
  • 18 Years - VISION and IVY Networks, September 2023-January 2024. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • 18 years with immunocompromising conditions - VISION Network, September 2023-February 2024. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • COVID-19 vaccination coverage and factors associated with vaccine uptake among people with HIV. 
    JAMA network open. 2024
  • Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 
    Clinical Infectious Diseases. 2024
  • Coronavirus disease 2019 (COVID-19) vaccination and stillbirth in the Vaccine Safety Datalink. 
    Obstetrics and Gynecology. 2024
  • Influenza vaccination accuracy among adults: self-report compared with electronic health record data. 
    Vaccine. 2024
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 
    Journal of Infectious Diseases. 2024
  • Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • Lack of evidence for vaccine-associated enhanced disease from COVID-19 vaccines among adults in the Vaccine Safety Datalink. 
    Pharmacoepidemiology and Drug Safety. 2024
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 
    Lancet (London, England). 2024
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 
    Influenza and other respiratory viruses. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 
    Clinical Infectious Diseases. 2024
  • A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. 
    Vaccine. 2023
  • Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. 
    American Journal of Epidemiology. 2023
  • Association between aluminum exposure from vaccines before age 24 months and persistent asthma at age 24 to 59 months. 
    Academic Pediatrics. 2023
  • COVID-19 booster vaccination in early pregnancy and surveillance for spontaneous abortion. 
    JAMA network open. 2023
  • COVID-19 vaccine safety surveillance in early pregnancy in the United States: design factors affecting the association between vaccine and spontaneous abortion. 
    American Journal of Epidemiology. 2023
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2023
  • Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 
    Pediatrics. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 
    Vaccine. 2023
  • Effectiveness of the original monovalent coronavirus disease 2019 vaccines in preventing emergency department or urgent care encounters and hospitalizations among adults with disabilities: VISION Network, June 2021-September 2022. 
    Open forum infectious diseases. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    American Journal of Transplantation. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    MMWR: Morbidity and Mortality Weekly Report. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 
    JAMA network open. 2023
  • Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. 
    Vaccine. 2023
  • Influenza vaccination among pregnant women: self-report compared with vaccination data from electronic health records, 2018-2020 influenza seasons. 
    Public Health Reports. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 
    Journal of Infectious Diseases. 2023
  • Safety of measles, mumps, and rubella vaccine in adolescents and adults in the Vaccine Safety Datalink. 
    Vaccine. 2023
  • Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. 
    Vaccine. 2023
  • Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. 
    Vaccine. 2023
  • Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. 
    Vaccine. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 
    Journal of Infectious Diseases. 2023
  • Association of the COVID-19 pandemic with routine childhood vaccination rates and proportion up to date with vaccinations across 8 US health systems in the Vaccine Safety Datalink. 
    JAMA pediatrics. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 
    JAMA network open. 2022
  • Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. 
    JAMA network open. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 
    Pediatrics. 2022
  • Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. 
    Pediatrics. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 
    BMJ (Clinical research ed.). 2022
  • 16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes. 
    JAMA network open. 2021
  • Developing algorithms for identifying major structural birth defects using automated electronic health data. 
    Pharmacoepidemiology and Drug Safety. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 
    New England Journal of Medicine. 2021
  • Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. 
    Vaccine. 2021
  • Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-August 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination. 
    JAMA. 2021
  • Temporal trends in undervaccination: a population-based cohort study. 
    American Journal of Preventive Medicine. 2021
  • The childhood vaccination schedule and the lack of association with type 1 diabetes. 
    Pediatrics. 2021
  • Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 
    Therapeutic advances in drug safety. 2021
  • Association between rotavirus vaccination and type 1 diabetes in children. 
    JAMA pediatrics. 2020
  • Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink. 
    Obstetrics and Gynecology. 2020
  • SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020. 
    MMWR: Morbidity and Mortality Weekly Report. 2020
  • Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. 
    Vaccine. 2019
  • Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. 
    Vaccine. 2019
  • Infant hospitalizations and mortality after maternal vaccination. 
    Pediatrics. 2018
  • Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. 
    Obstetrics and Gynecology. 2018
  • Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. 
    Pharmacoepidemiology and Drug Safety. 2018
  • The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study. 
    Pharmacoepidemiology and Drug Safety. 2018
  • Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. 
    Vaccine. 2018
  • Congenital microcephaly: case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. 
    Vaccine. 2017
  • Febrile seizure risk after vaccination in children one to five months of age. 
    Pediatric Neurology. 2017
  • First trimester influenza vaccination and risks for major structural birth defects in offspring. 
    Journal of Pediatrics. 2017
  • Identifying birth defects in automated data sources in the Vaccine Safety Datalink. 
    Pharmacoepidemiology and Drug Safety. 2017
  • Maternal Tdap vaccination and risk of infant morbidity. 
    Vaccine. 2017
  • Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. 
    Obstetrics and Gynecology. 2017
  • Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. 
    BMC Pulmonary Medicine. 2017
  • Febrile seizure risk after vaccination in children 6 to 23 months. 
    Pediatrics. 2016
  • Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink. 
    American Journal of Preventive Medicine. 2016
  • Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. 
    Vaccine. 2016
  • Risk of anaphylaxis after vaccination in children and adults. 
    Journal of Allergy and Clinical Immunology. 2016
  • Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies. 
    American Journal of Epidemiology. 2016
  • Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. 
    JAMA. 2015
  • Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. 
    Vaccine. 2015
  • Safety of measles-containing vaccines in 1-year-old children. 
    Pediatrics. 2015
  • Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. 
    Obstetrics and Gynecology. 2015
  • Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. 
    JAMA. 2014
  • Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites. 
    Preventive Medicine. 2014
  • Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. 
    Vaccine. 2014
  • Vaccinations given during pregnancy, 2002-2009: a descriptive study. 
    American Journal of Preventive Medicine. 2014
  • Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. 
    JAMA pediatrics. 2013
  • Measles-containing vaccines and febrile seizures in children age 4 to 6 years. 
    Pediatrics. 2012
  • Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. 
    Vaccine. 2011
  • Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. 
    Archives of Pediatrics and Adolescent Medicine. 2011
  • Lack of association between acellular pertussis vaccine and seizures in early childhood. 
    Pediatrics. 2010
  • Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. 
    Pediatrics. 2010
  • Varicella vaccination and ischemic stroke in children: is there an association?. 
    Pediatrics. 2009
  • Review
  • The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety [review]. 
    Vaccine. 2014
  • Contact
    full name
  • N. P. Klein
  • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration